Mental or Behavioral Dysfunction

Fierce Biotech Fundraising Tracker ’25: Grin Raises $140M Series D and Strikes Major Angelini Deal; Syndeio Secures $90M

2 weeks ago talkbio0Tagged Angelini Pharma, Blackstone Life Sciences, Grin, Neurodevelopmental Disorders, pharma partnerships, radiprodil, Series D financing, Syndeio

Grin Therapeutics; Series D financing; radiprodil; Angelini Pharma; Blackstone Life Sciences; Syndeio; biotech fundraising; neurodevelopmental disorders; pharma partnerships

Bristol Myers’ schizophrenia drug Cobenfy stumbles as adjunctive treatment, denting blockbuster plan

2 months ago talkbio0Tagged Adjunctive Orthodontic Procedure, Antipsychotic Agents, Cobenfy, Improvement, Myers, Schizophrenia, Single Agent Therapy, Statistical Significance

Cobenfy, Schizophrenia, Antipsychotic Agents, Adjunctive Orthodontic Procedure, Myers, Statistical Significance, Improvement, Single Agent Therapy

Leaked HHS budget signals $40B in cuts, assumes ACA subsidies expire

2 months ago talkbio0Tagged Administration occupational activities, Agencies, assumes, Budgets, HHS, Leaked, Patient Protection and Affordable Care Act, Programs - Publication Format, proposal - intent, Subsidies

Budgets, HHS, Patient Protection and Affordable Care Act, Subsidies, Agencies, Leaked, Administration occupational activities, proposal – intent, assumes, Programs – Publication Format

RFK Jr. attacks environmental toxins as cause of childhood autism ‘epidemic’, stays silent on vaccines

2 months ago talkbio0Tagged Autistic Disorder, Environment, HHS, Kennedy, RFK gene, Vaccines

Autistic Disorder, Vaccines, Kennedy, Environment, RFK gene, HHS

Leqembi wins EU authorization for some Alzheimer’s patients, giving Biogen, Eisai a boost over Lilly

2 months ago talkbio0Tagged Alzheimer, Apolipoprotein E4, ARIA, authorization, Biogen, Eisai, Eli Lilly, EU, High, Kisunla, Leqembi, Restricted

Leqembi, EU, Eisai, Eli Lilly, ARIA, Biogen, authorization, Alzheimer, Kisunla, Restricted, Apolipoprotein E4, High

Alzheon Investigates Subgroup Data Following Phase 3 Trial of ALZ-801 in Alzheimer’s Disease

2 months ago talkbio0Tagged ALZ-801, Alzheimer 's disease, Amyloid-targeting therapy, Apolipoprotein E4, Genotype, Mental deterioration, Mild cognitive disorder, Phase 3 trial, Precision Medicine, Subgroup A Nepoviruses, Valiltramiprosate

Alzheimer’s disease , ALZ-801 , Valiltramiprosate , APOE4 genotype , Mild cognitive impairment (MCI) , Amyloid-targeting therapy , Phase 3 trial results , Cognitive decline , Subgroup analysis , Precision medicine